Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - PR Newswire

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals  PR Newswire

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - PR Newswire

Click here to get full coverage on Harrow stock wins William Blair's new Outperform (HROW:NASDAQ) - Seeking Alpha

Harrow stock wins William Blair's new Outperform (HROW:NASDAQ)  Seeking Alpha

Harrow stock wins William Blair's new Outperform (HROW:NASDAQ) - Seeking Alpha

Click here to get full coverage on What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings  Yahoo Finance

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

Click here to get full coverage on Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications  Business Wire

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire

Click here to get full coverage on Assessing Harrow: Insights From 4 Financial Analysts - Nasdaq

Assessing Harrow: Insights From 4 Financial Analysts  Nasdaq

Assessing Harrow: Insights From 4 Financial Analysts - Nasdaq

Click here to get full coverage on Harrow (HROW) Secures Exclusive U.S. Rights for New Ophthalmic S - GuruFocus

Harrow (HROW) Secures Exclusive U.S. Rights for New Ophthalmic S  GuruFocus

Harrow (HROW) Secures Exclusive U.S. Rights for New Ophthalmic S - GuruFocus

Click here to get full coverage on TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News  Stock Titan

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Click here to get full coverage on Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha

Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW)  Seeking Alpha

Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee  Stock Titan

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan

Click here to get full coverage on BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook | HROW Stock News - GuruFocus

BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook | HROW Stock News  GuruFocus

BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook | HROW Stock News - GuruFocus

Click here to get full coverage on Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025  Business Wire

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire

Click here to get full coverage on Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...  Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)  Seeking Alpha

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership  Stock Titan

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Click here to get full coverage on HROW to Participate in Lake Street's Virtual Meeting on June 24 | HROW Stock News - GuruFocus

HROW to Participate in Lake Street's Virtual Meeting on June 24 | HROW Stock News  GuruFocus

HROW to Participate in Lake Street's Virtual Meeting on June 24 | HROW Stock News - GuruFocus

Click here to get full coverage on Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance  Business Wire

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire

Click here to get full coverage on Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...  Yahoo Finance

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Click here to get full coverage on Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives  Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Click here to get full coverage on Harrow (HROW) Secures U.S. Rights to BYQLOVI - GuruFocus

Harrow (HROW) Secures U.S. Rights to BYQLOVI  GuruFocus

Harrow (HROW) Secures U.S. Rights to BYQLOVI - GuruFocus

Click here to get full coverage on Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price - simplywall.st

Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price  simplywall.st

Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price - simplywall.st

Click here to get full coverage on Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”  Insider Monkey

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey

Click here to get full coverage on Major Dry Eye Treatment Breakthrough: VEVYE Opens Access to 25,000+ Patients with $59 Price Tag - Stock Titan

Major Dry Eye Treatment Breakthrough: VEVYE Opens Access to 25,000+ Patients with $59 Price Tag  Stock Titan

Major Dry Eye Treatment Breakthrough: VEVYE Opens Access to 25,000+ Patients with $59 Price Tag - Stock Titan

Click here to get full coverage on Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025  Seeking Alpha

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha

Click here to get full coverage on I Am Swimming In Dividends With +7% Yields - Seeking Alpha

I Am Swimming In Dividends With +7% Yields  Seeking Alpha

I Am Swimming In Dividends With +7% Yields - Seeking Alpha

Click here to get full coverage on Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Harrow Soars On Preliminary Q4 Results, Revenue Outlook  RTTNews

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Click here to get full coverage on Harrow (HROW) Gains Coverage with Outperform Rating Following Licensing Deal - GuruFocus

Harrow (HROW) Gains Coverage with Outperform Rating Following Licensing Deal  GuruFocus

Harrow (HROW) Gains Coverage with Outperform Rating Following Licensing Deal - GuruFocus

Click here to get full coverage on Harrow Announces First-Quarter 2025 Financial Results - Business Wire

Harrow Announces First-Quarter 2025 Financial Results  Business Wire

Harrow Announces First-Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Harrow Announces Third Quarter 2024 Financial Results - Business Wire

Harrow Announces Third Quarter 2024 Financial Results  Business Wire

Harrow Announces Third Quarter 2024 Financial Results - Business Wire

Click here to get full coverage on Noteworthy Tuesday Option Activity: BECN, HROW, HUM - Nasdaq

Noteworthy Tuesday Option Activity: BECN, HROW, HUM  Nasdaq

Noteworthy Tuesday Option Activity: BECN, HROW, HUM - Nasdaq

Click here to get full coverage on NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - PR Newswire

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)  PR Newswire

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - PR Newswire

Click here to get full coverage on Noteworthy Friday Option Activity: SNOW, OUST, HROW - Nasdaq

Noteworthy Friday Option Activity: SNOW, OUST, HROW  Nasdaq

Noteworthy Friday Option Activity: SNOW, OUST, HROW - Nasdaq

Click here to get full coverage on Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results  Business Wire

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire

Click here to get full coverage on Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol  Seeking Alpha

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Click here to get full coverage on Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®  Business Wire

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Click here to get full coverage on Harrow Appoints Mike Biega as Vice President of Investor Relatio - GuruFocus

Harrow Appoints Mike Biega as Vice President of Investor Relatio  GuruFocus

Harrow Appoints Mike Biega as Vice President of Investor Relatio - GuruFocus

Click here to get full coverage on Harrow Health Approves Key Proposals at Annual Meeting - TipRanks

Harrow Health Approves Key Proposals at Annual Meeting  TipRanks

Harrow Health Approves Key Proposals at Annual Meeting - TipRanks

Click here to get full coverage on Those Derisked Baby Bonds Of Harrow, Inc (NASDAQ:HROWM) - Seeking Alpha

Those Derisked Baby Bonds Of Harrow, Inc (NASDAQ:HROWM)  Seeking Alpha

Those Derisked Baby Bonds Of Harrow, Inc (NASDAQ:HROWM) - Seeking Alpha

Click here to get full coverage on William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy - Harrow (NASDAQ:HROW) - Benzinga

William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy - Harrow (NASDAQ:HROW)  Benzinga

William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy - Harrow (NASDAQ:HROW) - Benzinga

Click here to get full coverage on Harrow Announces Market Access Wins for VEVYE® - Business Wire

Harrow Announces Market Access Wins for VEVYE®  Business Wire

Harrow Announces Market Access Wins for VEVYE® - Business Wire

Click here to get full coverage on Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 - Business Wire

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025  Business Wire

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 - Business Wire

Click here to get full coverage on Harrow Appoints Amir H. Shojaei as Chief Scientific Officer - Business Wire

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer  Business Wire

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer - Business Wire

Click here to get full coverage on Harrow Health earnings missed by $0.56, revenue fell short of estimates - Investing.com

Harrow Health earnings missed by $0.56, revenue fell short of estimates  Investing.com

Harrow Health earnings missed by $0.56, revenue fell short of estimates - Investing.com

Click here to get full coverage on Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Mark  GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus

Click here to get full coverage on Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts - Investing.com

Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts  Investing.com

Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts - Investing.com

Click here to get full coverage on Harrow: VEVYE Excluded from Stand-Alone Part D Plans in 2025, Amid Company’s Claims of ‘Market Access Win’ in Medicare - The Capitol Forum

Harrow: VEVYE Excluded from Stand-Alone Part D Plans in 2025, Amid Company’s Claims of ‘Market Access Win’ in Medicare  The Capitol Forum

Harrow: VEVYE Excluded from Stand-Alone Part D Plans in 2025, Amid Company’s Claims of ‘Market Access Win’ in Medicare - The Capitol Forum

Click here to get full coverage on Harrow Relaunches TRIESENCE® - Business Wire

Harrow Relaunches TRIESENCE®  Business Wire

Harrow Relaunches TRIESENCE® - Business Wire

Click here to get full coverage on Harrow Announces Nashville Expansion - Business Wire

Harrow Announces Nashville Expansion  Business Wire

Harrow Announces Nashville Expansion - Business Wire

Click here to get full coverage on Harrow Announces Second Quarter 2024 Financial Results - Business Wire

Harrow Announces Second Quarter 2024 Financial Results  Business Wire

Harrow Announces Second Quarter 2024 Financial Results - Business Wire

Click here to get full coverage on Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.  Business Wire

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire

Click here to get full coverage on Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com Australia

Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com  Investing.com Australia

Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com Australia

Click here to get full coverage on Harrow Provides TRIESENCE® Relaunch Update - Business Wire

Harrow Provides TRIESENCE® Relaunch Update  Business Wire

Harrow Provides TRIESENCE® Relaunch Update - Business Wire

Click here to get full coverage on Harrow Successfully Manufactures Triesence; Management Credibility Soars (HROW) - Seeking Alpha

Harrow Successfully Manufactures Triesence; Management Credibility Soars (HROW)  Seeking Alpha

Harrow Successfully Manufactures Triesence; Management Credibility Soars (HROW) - Seeking Alpha

Click here to get full coverage on CEO Mark Baum Acquires 9,000 Shares of Harrow Inc (HROW) - Yahoo Finance

CEO Mark Baum Acquires 9,000 Shares of Harrow Inc (HROW)  Yahoo Finance

CEO Mark Baum Acquires 9,000 Shares of Harrow Inc (HROW) - Yahoo Finance

Click here to get full coverage on Harrow Prices $60 Million Public Offering of Common Stock - Business Wire

Harrow Prices $60 Million Public Offering of Common Stock  Business Wire

Harrow Health Inc (HROW)

Price Chart

Key Statistics

Technicals

About HROW

Latest News

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - PR Newswire

Harrow stock wins William Blair's new Outperform (HROW:NASDAQ) - Seeking Alpha

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers